

To,  
**BSE Limited**  
P.J. Towers, Dalal Street  
Mumbai - 400001

**Sub: Outcome of Board Meeting held on 13.02.2026 under Regulation 30 read with 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Unit: Bandaram Pharma Packtech Limited (Scrip Code: 524602)**

Dear Sir/Madam,

With reference to the above mentioned subject, this is to inform the Exchange that the Board of Directors of Bandaram Pharma Packtech Limited in its meeting held on Friday, the 13<sup>th</sup> day of February, 2026 at 4:30 p.m. at the Registered Office of the Company at 601,5th Floor, Oxford Towers, opp to Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore, Bangalore, Karnataka, India, 560008 has considered and approved the following item:

1. Un-audited financial Results (Standalone and Consolidated) along with the Limited Review Report (Standalone and Consolidated) as per Regulation 33 of SEBI (LODR) Regulations, 2015, for the quarter and nine months ended 31.12.2025. **(Enclosed)**

The meeting concluded at 7:10 p.m.

We request you to kindly take note of the same in your records.

Thanking you.

Yours sincerely,  
**For Bandaram Pharma Packtech Limited**

DEEPAK  
REDDY B

Digitally signed by  
DEEPAK REDDY B  
Date: 2026.02.13  
19:13:22 +05'30'

**Deepak Reddy B**  
**Chairman and Managing Director**  
**(DIN: 07074102)**

**Encl: a/a**

**BANDARAM PHARMA PACKTECH LIMITED**

**CIN: L93090KA1993PLC159827**

**www.bandaram.com,**

**Reg office, Oxford towers, Unit No. 601, 5th Floor, Old Airport Road, Kodihalli, Bangalore-560008**

**E Mail: info.bandaram@gmail.com Phone No. 080 40952127**

**BANDARAM PHARMA PACKTECH LIMITED**

**(Formerly Known as Shiva Medicare Limited)**

**CIN: L93090KA1993PLC159827**

**Regd Office: 601,5th Floor, Oxford Towers, Opp. to Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore - 560008.**

**Statement of Unaudited Results for the Quarter Ended and Nine Months Ended 31.12.2025**

**(Amount Rs. in lakhs)**

S.No.	Particulars	STAND ALONE						CONSOLIDATED					
		For the Quarter ended			Nine Months ended		Previous Year ended	For the Quarter ended			Nine Months ended		Previous Year ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)	31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
I.	Revenue from Operations	167.67	32.93	263.15	276.34	851.91	1,222.83	1,483.55	1,372.48	999.80	3,731.56	2,847.26	3,696.38
II.	Other Income	-	0.83	-	0.83	-	9.39	-	0.83	-	0.83	-	9.39
III.	<b>Total income (I+II)</b>	<b>167.67</b>	<b>33.76</b>	<b>263.15</b>	<b>277.17</b>	<b>851.91</b>	<b>1,232.22</b>	<b>1,483.55</b>	<b>1,373.31</b>	<b>999.80</b>	<b>3,732.39</b>	<b>2,847.26</b>	<b>3,705.77</b>
IV.	<b>Expenses</b>												
	(a) Cost of Materials consumed	166.33	32.92	237.82	274.64	732.97	1,043.89	1,402.49	1,088.57	812.13	3,178.19	2,657.80	3,096.15
	(b) Purchase of stock-in-trade	-	-	-	-	-	-	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-	-143.89	142.73	26.10	-2.94	-347.47	(131.13)
	(d) Employee benefits expenses	11.41	10.97	16.44	33.12	64.49	109.74	57.66	52.91	59.53	162.18	187.31	295.73
	(e) Finance Cost	-	0.03	-	0.03	-	0.02	33.45	25.20	23.94	104.67	71.20	61.27
	(f) Depreciation and amortisation expenses	0.05	0.06	0.18	0.16	0.54	0.56	13.53	13.62	15.18	40.59	45.54	98.70
	(h) Other expenses	11.02	24.52	4.02	51.95	41.00	59.49	67.31	42.51	36.37	160.39	121.31	153.45
	<b>Total Expenses</b>	<b>188.81</b>	<b>68.50</b>	<b>258.46</b>	<b>359.90</b>	<b>839.00</b>	<b>1,213.70</b>	<b>1,430.55</b>	<b>1,365.54</b>	<b>973.25</b>	<b>3,643.08</b>	<b>2,735.69</b>	<b>3,574.17</b>
V.	<b>Profit / (Loss) before and exceptional items and Tax (III-IV)</b>	<b>(21.14)</b>	<b>(34.74)</b>	<b>4.69</b>	<b>(82.73)</b>	<b>12.91</b>	<b>18.52</b>	<b>53.00</b>	<b>7.77</b>	<b>26.55</b>	<b>89.31</b>	<b>111.57</b>	<b>131.60</b>
VI.	Exceptional Items	-	-	-	-	-	-	-	-	-	-	-	-
VII.	<b>Profit / (Loss) from before tax (V-VI)</b>	<b>(21.14)</b>	<b>(34.74)</b>	<b>4.69</b>	<b>(82.73)</b>	<b>12.91</b>	<b>18.52</b>	<b>53.00</b>	<b>7.77</b>	<b>26.55</b>	<b>89.31</b>	<b>111.57</b>	<b>131.60</b>
VIII.	<b>Tax expense</b>												
	Current Tax	-	-	3.23	-	3.23	4.63	18.23	1.94	27.89	22.33	27.89	32.90
	Deferred Tax	-	0.04	(0.01)	-	(0.01)	(0.11)	(0.17)	(0.20)	-	(0.51)	-	(0.68)
IX.	<b>Net Profit / (Loss) for the period from Continuing operations (VII-VIII)</b>	<b>(21.14)</b>	<b>(34.78)</b>	<b>1.47</b>	<b>(82.73)</b>	<b>9.69</b>	<b>14.00</b>	<b>34.95</b>	<b>6.03</b>	<b>(1.34)</b>	<b>67.49</b>	<b>83.68</b>	<b>99.38</b>

X	Profit/ (Loss) from discontinuing operations												
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-	-	-	-	-	-	-
XII	<b>Profit/ (Loss) from discontinuing operations after tax</b>	-	-	-	-	-	-	-	-	-	-	-	-
XIII	<b>Profit/(loss) for the Period (IX+XII)</b>	<b>(21.14)</b>	<b>(34.78)</b>	<b>1.47</b>	<b>(82.73)</b>	<b>9.69</b>	<b>14.00</b>	<b>34.95</b>	<b>6.03</b>	<b>(1.34)</b>	<b>67.49</b>	<b>83.68</b>	<b>99.38</b>
XIV	<b>Other Comprehensive Incomes</b>												
A.	(i) Items that will not be recycled to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
	(a) Others (gratuity and leave encashment excess provision reversal)	-	-	-	-	-	-	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
B.	(i) Items that may be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
	(ii) Income tax on items that may be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
	<b>Total Comprehensive Income</b>	-	-	-	-	-	-	-	-	-	-	-	-
XV	<b>Total Comprehensive Income for the period (XIII+XIV)</b>	<b>(21.14)</b>	<b>(34.78)</b>	<b>1.47</b>	<b>(82.73)</b>	<b>9.69</b>	<b>14.00</b>	<b>34.95</b>	<b>6.03</b>	<b>(1.34)</b>	<b>67.49</b>	<b>83.68</b>	<b>99.38</b>
	<b>Attributable to Shareholders of Bandaram Pharma Packtech Limited</b>	-	-	-	-	-	-	<b>19.22</b>	<b>3.32</b>	<b>(0.74)</b>	<b>37.12</b>	<b>46.02</b>	<b>54.66</b>
	<b>Non Controlling Interest</b>	-	-	-	-	-	-	<b>15.73</b>	<b>2.71</b>	<b>(0.60)</b>	<b>30.37</b>	<b>37.66</b>	<b>44.72</b>
XVI	<b>Earnings Per Equity Share of face value of Rs.10/- each)(for Countinuing opertions):</b>	-	-	-	-	-	-						
	1) Basic	<b>(0.12)</b>	<b>(0.29)</b>	<b>0.01</b>	<b>(0.46)</b>	<b>0.08</b>	<b>0.12</b>	<b>0.11</b>	<b>0.03</b>	<b>(0.01)</b>	<b>0.21</b>	<b>0.38</b>	<b>0.46</b>
	2) Diluted	<b>(0.12)</b>	<b>(0.29)</b>	<b>0.01</b>	<b>(0.46)</b>	<b>0.08</b>	<b>0.12</b>	<b>0.11</b>	<b>0.03</b>	<b>(0.01)</b>	<b>0.21</b>	<b>0.38</b>	<b>0.46</b>

XVII	<b>Earnings Per Equity Share of face value of Rs.10/- each) (for Discontinuing operations):</b>												
	1) Basic	(0.12)	(0.29)	0.01	(0.46)	0.08	0.12	0.11	0.03	(0.01)	0.21	0.38	0.46
	2) Diluted	(0.12)	(0.29)	0.01	(0.46)	0.08	0.12	0.11	0.03	(0.01)	0.21	0.38	0.46
XVIII	<b>Earnings Per Equity Share of face value of Rs.10/- each) (for Continued and Discontinuing operations):</b>												
	1) Basic	(0.12)	(0.29)	0.01	(0.46)	0.08	0.12	0.11	0.03	(0.01)	0.21	0.38	0.46
	2) Diluted	(0.12)	(0.29)	0.01	(0.46)	0.08	0.12	0.11	0.03	(0.01)	0.21	0.38	0.46
XIX	Paid-up equity share capital (Face Value of Rs. 10/- per share)	1,797.19	1,200.00	1,200.00	1,797.19	1,200.00	1,200.00	1,797.19	1,200.00	1,200.00	1,797.19	1,200.00	1,200.00

**Notes:**

1. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of the Companies Act, 2013, the above Financial Results have been prepared. The same is reviewed by the Statutory Auditors of Company and recommended by the Audit Committee and subsequently approved by the Board of Directors of Company at their meeting held on 13-02-2026.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS-34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting pronouncements generally accepted in India.
3. The figures of the previous year/periods have been re-grouped/re-classified, wherever necessary, for the purpose of comparison with the current year/period figures.
4. Segmentwise report as per Ind AS -108, is not applicable.
5. The above Financial Results are also available on the company's website [www.bandaram.com](http://www.bandaram.com)
6. The consolidated results includes VSR Paper & Packaging Limited (55% share held by Bandaram Pharma Packtech Limited) and Craftsmart Products Private Limited (100% held by Bandaram Pharma Packtech Limited)
7. The Bandaram Pharma Packtech Limited has acquired shareholders of Craftsmart Products Private Limited on swap basis in the ratio of 5:4 (i.e., for every 5 Equity shares of Rs. 10/- each held in Craftsmart Products Private Limited, 4 Equity shares of Rs. 10/- each of Bandaram Pharma Packtech Limited will be issued) with distinctive number/range from 1,20,00,001 to 1,79,71,920 in dematerialized form

For and on Behalf of the Board of Directors  
Bandaram Pharma Packtech Limited  
(Formerly Known as Shiva Medicare Limited)

B. Deepak Reddy  
Chairman & Managing Director  
DIN: 07074102



Place : Bangalore  
Date : 13-02-2026



**LIMITED REVIEW REPORT**

To,  
**The Board of Directors,**  
**BANDARAM PHARMA PACKTECH LIMITED**

We have reviewed the accompanying statement of Un-Audited Financial Results of **BANDARAM PHARMA PACKTECH LIMITED (formerly known as Shiva Medicare Limited)** for the quarter ended **31<sup>st</sup> December 2025** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ( "Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **M M REDDY & CO.,**  
Chartered Accountants  
Firm Regn No 010371S

M Madhusudhana Reddy  
Partner

Membership No 2130770371S  
UDIN: **26213077LAYYKR1938**

Place: Hyderabad  
Date: 13-02-2026






**Independent Auditor's Review Report on Interim Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
Board of Directors of  
**BANDARAM PHARMA PACKTECH LIMITED**

We have reviewed the quarterly Consolidated Unaudited Financial Results of **BANDARAM PHARMA PACKTECH LIMITED (formerly known as Shiva Medicare Limited)** ("The Company") and its subsidiaries (Collectively referred to as Group) for the quarter ended 31<sup>st</sup> December 2025 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

These quarterly consolidated financial results as well have been prepared on the basis of the consolidated interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these Consolidated financial results based on our audit of such Consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our review of the Statement in accordance with the standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Attention is drawn to the statement which states that the Consolidated figures for the Corresponding quarters ended September 30, 2025 as reported in the accompanying Statement have been approved by the Parent's Board of Directors, but have not been subjected to review.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

We did not review the interim financial information of Subsidiary company which are included in the consolidated quarterly unaudited financial results, whose consolidated interim financial information reflects, total revenues of VSR Paper and Packaging Limited is Rs. 1398.76 Lakhs for the quarter ended 31<sup>st</sup> December 2025, total net profit of VSR Paper and Packaging Limited is Rs. 73.76 Lakhs and total comprehensive income/(loss) of VSR Paper and Packaging Limited is 55.71 Lakhs for the quarter ended 31<sup>st</sup> December, 2025. And total revenues of Craftsmart Products Private Limited Rs.25.38 Lakhs and total netprofit 0.38 Lakhs. This interim financial information has been reviewed by other Auditors whose reports have been furnished to us by management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, based solely on the reports of the other auditors.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results:

- I. Include the quarterly financial results of the following entities: -
  - a) VSR Paper and Packaging Limited (Holding 55%)
  - b) Craftsmart Products Private Limited (Holding 100%)
- II. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard.

For M M REDDY & CO.,  
Chartered Accountants  
Firm Regn No.010371S

M. Madhusudhana Reddy  
Partner

Membership No.213077  
UDIN:26213077QRPNKG4382



Place: Hyderabad  
Date: 13-02-2026